Aqualung Therapeutics Corp. has been awarded two 3-year National Institutes of Health (NIH) Fast Track awards to support development of ALT-100 (enamptcumab), a humanized monoclonal antibody therapy for the chronic indications of pulmonary arterial hypertension (PAH) and inflammatory bowel disease (IBD).

Researchers have designed a 3D model of lung cancer that is composed of bronchial epithelial, fibroblasts, epithelial, lung adenocarcinoma and immune cells grown in different layers in a matrigel.

The University of Bari Aldo Moro presented data from an in vivo study assessing the effects of irisin on pancreatic islets of diabetic mice (type 2 diabetes).

Abpro Corp. has entered into a strategic partnership with Celltrion Holdings Co. Ltd. for ABP-102, a bispecific antibody therapy for patients with HER2+ cancer, including breast, gastric and pancreatic cancers.

Autosomal dominant hypocalcemia (ADH) type 1 and 2 are disorders that affect calcium homeostasis caused by gain-of-function mutations in CaSR, which encodes the calcium-sensing receptor.

Researchers from Consejo Superior de Investigaciones Cientificas (CSIC) and affiliated organizations presented the discovery of a novel series of compounds acting as Ebola virus (EBOV) entry inhibitors.

Investigators at Washington State University (WSU) have identified a set of eight proteins that were expressed in the serum of Ursus arctos horribilis, better known as the grizzly bear, specifically during their hibernation period. In addition to reporting new basic insights into hibernation, the study, which was published in the Sept. 21, 2022, issue of iScience, could also give clues to insulin resistance and its relationship to body fat.